Disc Medicine, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−0.69%
vs ±8.5% implied · ×0.08
shaded = implied · ▲▼ = realized
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $358.0M | 11.32% | −12.39% |
| BlackRockindex-like | $180.5M | 5.71% | +8.53% |
| RA Capital Management | $179.2M | 5.67% | 0.00% |
| JPMorgan Chase | $139.9M | 4.42% | +36.77% |
| T. Rowe Price | $137.2M | 4.34% | +21.04% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $358.0M | 11.32% | −12.39% |
| BlackRockindex-like | $180.5M | 5.71% | +8.53% |
| RA Capital Management | $179.2M | 5.67% | 0.00% |
| JPMorgan Chase | $139.9M | 4.42% | +36.77% |
| T. Rowe Price | $137.2M | 4.34% | +21.04% |
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Disc Medicine, Inc.
83.35
Bull2
Bear1
Linked news
NewsGemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Disc Medicine, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Disc Medicine, Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
—
Expected move
Inputsspot 83.28exp Mar 19ATM strike 85ATM straddle 19.30IV 48%